Evidence map›Paper›PMID 41008875›Full record

ArticleCancers2025

Application of the STRATCANS Criteria to the MUSIC Prostate Cancer Active Surveillance Cohort: A Step Towards Risk-Stratified Active Surveillance.

Ana M Moser, Michael Wang, Ava Zamani, Sabir Meah, Stephanie Daignault-Newton, Corinne Labardee, Nicholas Dybas, Jacob Clapper, Brian R Lane, Tudor Borza and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ana M MoserDepartment of Urology, Wayne State University, Detroit, MI 48202, USA.ORCID 0009-0008-7885-8804
Michael WangDepartment of Urology, Wayne State University, Detroit, MI 48202, USA.
Ava ZamaniDepartment of Urology, Wayne State University, Detroit, MI 48202, USA.ORCID 0009-0004-6381-0614
Sabir MeahDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0009-0006-4101-3221
Stephanie Daignault-NewtonDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0001-6355-0710
Corinne LabardeeDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
Nicholas DybasDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
Jacob ClapperDepartment of Urology, Capital Urology Associates, Marshall, MI 49068, USA.
Brian R LaneDivision of Urology, Corewell Health West, Grand Rapids, MI 49506, USA.
Tudor BorzaDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
Alice SemerjianDepartment of Urology, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0002-8031-993X
Vincent J GnanapragasamDepartment of Surgery, Division of Urology, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0003-4722-4207
Kevin B GinsburgDepartment of Urology, Wayne State University, Detroit, MI 48202, USA.

Funding

Blue Cross Blue Shield of Michigan Foundation N/A
6 · The paper itself

Abstract

backgroundThe STRATified CANcer Surveillance (STRATCANS) model risk-stratifies patients with prostate cancer (PC) on active surveillance (AS) into three tiers based on their risk of disease progression. We applied STRATCANS to the Michigan Urological Surgery Improvement Collaborative (MUSIC) Prostate registry to assess its association with the risk of biopsy upgrading and time to definitive treatment in a diverse, real-world AS cohort.

methodsWe retrospectively reviewed the MUSIC registry for PC patients on AS from 2016 to 2022 and classified patients by STRATCANS tier. Primary outcomes included biopsy upgrading to ≥Grade Group 3 (≥GG3), any biopsy upgrading, and time to definitive treatment.

resultsAmong 7578 men on AS, 4009, 2732, and 837 patients were in STRATCANS 1, 2, and 3, respectively. The risk of progression to ≥GG3 was 13%, 33%, and 53% for patients in STRATCANS 1, 2, and 3, respectively (

conclusionsSTRATCANS has a stepwise association with the risk of progression to ≥GG3 disease and time to definitive treatment among men on AS in the MUSIC cohort, supporting its use as a risk-based, follow-up approach in men on AS.

Indexed as

active surveillancefollow-upprostate cancerrisk-stratifiedSTRATCANSurologic oncology

Identifiers

PMID41008875
PMCPMC12468819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.